AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33745547 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and glucocorticoids (Ponticelli regimen)
Number of subjects: 0
Study 33198820 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate diet with or without physical activity
Number of subjects: 120
Study 33198820 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet with or without physical activity
Number of subjects: 120
Study 33198820 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline DNA methylation score
Number of subjects: 120
Study 33122344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × N-AVD (doxorubicin, vinblastine, dacarbazine with two concomitant nivolumab infusions per cycle)
Number of subjects: 59
Study 33122344 — intervention group
Group type: COMPARATOR
Intervention: 4 × nivolumab
Number of subjects: 59
Study 33153707 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mitomycin C
Number of subjects: 40
Study 33153707 — intervention group
Group type: COMPARATOR
Intervention: Intra-lesional mitomycin C
Number of subjects: 40
Study 34219588 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 44
Study 33929630 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of dental radiographs by dentists
Number of subjects: 21
Study 33929630 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic experience
Number of subjects: 21
Study 33929630 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of study participants
Number of subjects: 21
Study 35280171 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 300
Study 35280171 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 300
Study 32301501 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2982772, 60 mg twice daily (b.i.d.)
Number of subjects: 65
Study 32301501 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2982772, 60 mg three times daily (t.i.d.)
Number of subjects: 65
Study 32301501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 32301501 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2982772
Number of subjects: 65
Study 35206443 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Ketogenic Diet (VLCKD)
Number of subjects: 26
Study 35206443 — intervention group
Group type: COMPARATOR
Intervention: Low Caloric Diet (LCD)
Number of subjects: 26
Study 34320288 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV hyperimmune globulin (100 mg/kg monthly until delivery)
Number of subjects: 399
Study 34320288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 34320288 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV hyperimmune globulin
Number of subjects: 399
Study 34910320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 60
Study 34910320 — intervention group
Group type: COMPARATOR
Intervention: Sertaconazole 2% cream
Number of subjects: 60
Study 33048569 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental Friendship Coaching (PFC)
Number of subjects: 172
Study 33048569 — intervention group
Group type: COMPARATOR
Intervention: Coping with ADHD through Relationships and Education (CARE)
Number of subjects: 172
Study 34740101 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 63
Study 34740101 — intervention group
Group type: COMPARATOR
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 63
Study 32954885 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Cardiac Rehabilitation (HBCR)
Number of subjects: 237
Study 32954885 — intervention group
Group type: COMPARATOR
Intervention: Facility-Based Cardiac Rehabilitation (FBCR)
Number of subjects: 237
Study 34024233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 10 mg/kg infusion in 100 mL normal saline
Number of subjects: 207
Study 34024233 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water in 100 mL normal saline)
Number of subjects: 207
Study 34024233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 207
Study 33099848 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp (twice-daily single injection)
Number of subjects: 52
Study 33099848 — intervention group
Group type: COMPARATOR
Intervention: IDeg + Lira (once-daily dual injection)
Number of subjects: 52
Study 34212863 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1905
Study 34212863 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1905
Study 34212863 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary composite outcome (death, MI, stroke) after PCI
Number of subjects: 1905
Study 34212863 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary composite outcome (death, MI, stroke, IDR) after PCI
Number of subjects: 1905
Study 34138698 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecure ECE providers
Number of subjects: 216
Study 32246743 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (bodyweight-adjusted, administered once-daily, twice-daily, or thrice-daily)
Number of subjects: 335
Study 32246743 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (tablet and suspension formulation)
Number of subjects: 335
Study 32246743 — intervention group
Group type: COMPARATOR
Intervention: Standard anticoagulation
Number of subjects: 335
Study 34967053 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 16
Study 34967053 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Occupational Performance Measure (COPM)
Number of subjects: 16
Study 34967053 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Form (SF)-36 physical health component
Number of subjects: 16
Study 34500245 — intervention group
Group type: COMPARATOR
Intervention: Traditional PNF
Number of subjects: 223
Study 34500245 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media inspired gamified PNF
Number of subjects: 223
Study 34500245 — intervention group
Group type: COMPARATOR
Intervention: Gamified only PNF
Number of subjects: 223
Study 32476140 — intervention group
Group type: COMPARATOR
Intervention: Lower fat diet
Number of subjects: 57079
Study 36200921 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-filler serum (applied starting 24 hours after BoNTA injection, then twice daily for 24 weeks)
Number of subjects: 0
Study 36200921 — intervention group
Group type: COMPARATOR
Intervention: BoNTA (control group)
Number of subjects: 0
Study 32842336 — intervention group
Group type: EXPERIMENTAL
Intervention: LenSx
Number of subjects: 86
Study 32842336 — intervention group
Group type: COMPARATOR
Intervention: LenSAR
Number of subjects: 86
Study 33793285 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline psychological distress
Number of subjects: 513
Study 33793285 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 513
Study 33793285 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate income
Number of subjects: 513
Study 33793285 — intervention group
Group type: EXPERIMENTAL
Intervention: Low health literacy
Number of subjects: 513
Study 33793285 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one ADL deficit
Number of subjects: 513
Study 34343687 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB + EPD
Number of subjects: 95
Study 34343687 — intervention group
Group type: COMPARATOR
Intervention: BMS without EPD
Number of subjects: 95
Study 32098575 — intervention group
Group type: EXPERIMENTAL
Intervention: Death over Dinner
Number of subjects: 109
Study 32098575 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 109
Study 34857525 — intervention group
Group type: COMPARATOR
Intervention: Danazol 800 mg daily in two divided doses for adults or 2 mg/kg/day for children, escalating to 4 mg/kg/day if no side effects are encountered, for a total of 12 months for adults and 6 months for children.
Number of subjects: 0
Study 35504508 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3) implantation
Number of subjects: 1958
Study 33293274 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C concentrations <1.8 mmol/L (<70 mg/dL; 1st-5th centiles)
Number of subjects: 108243
Study 33293274 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C concentrations >4.8 mmol/L (>189 mg/dL; 96th-100th centiles)
Number of subjects: 108243
Study 33293274 — intervention group
Group type: COMPARATOR
Intervention: LDL-C concentration of 3.6 mmol/L (140 mg/dL)
Number of subjects: 108243
Study 33293274 — intervention group
Group type: COMPARATOR
Intervention: LDL-C concentration of 2.3 mmol/L (89 mg/dL)
Number of subjects: 108243
Study 33293274 — intervention group
Group type: EXPERIMENTAL
Intervention: Any increase in LDL-C levels
Number of subjects: 108243
Study 32905611 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - bolus dose of 10 mg kg−1 followed by 8 hours continuous infusion of 3 mg kg−1 h−1
Number of subjects: 30
Study 32905611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32916606 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower female hs‐cTn thresholds implemented in hospitals
Number of subjects: 30
Study 32916606 — intervention group
Group type: COMPARATOR
Intervention: Overall hs‐cTn thresholds for men
Number of subjects: 30
Study 32245305 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 40
Study 32245305 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy (COT)
Number of subjects: 40
Study 35149538 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib plus Olaparib
Number of subjects: 17
Study 33180007 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute beetroot juice supplementation (70 mL, 6.4 mmol NO3‐)
Number of subjects: 9
Study 33180007 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.005 mmol NO3‐)
Number of subjects: 9
Study 33998555 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning Walk®
Number of subjects: 36
Study 33998555 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (control group)
Number of subjects: 36
Study 35778796 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage combined with vacuum sealing drainage
Number of subjects: 102
Study 35778796 — intervention group
Group type: COMPARATOR
Intervention: Health education and functional training (Control)
Number of subjects: 102
Study 33949017 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-lead Holter recordings
Number of subjects: 40
Study 33949017 — intervention group
Group type: COMPARATOR
Intervention: Resting ECGs
Number of subjects: 40
Study 33949017 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous recordings
Number of subjects: 40
Study 34097862 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartfulness meditation
Number of subjects: 60
Study 34097862 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 32808409 — intervention group
Group type: EXPERIMENTAL
Intervention: Active soft tissue therapy (stretching exercise + active soft tissue therapy)
Number of subjects: 45
Study 32808409 — intervention group
Group type: EXPERIMENTAL
Intervention: Graston technique (stretching exercise + Graston technique)
Number of subjects: 45
Study 32808409 — intervention group
Group type: COMPARATOR
Intervention: Control group (stretching exercise only)
Number of subjects: 45
Study 33174199 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 cm head elevation (high group)
Number of subjects: 110
Study 33174199 — intervention group
Group type: COMPARATOR
Intervention: Conventional 7 cm head elevation (control group)
Number of subjects: 110
Study 34653651 — intervention group
Group type: COMPARATOR
Intervention: Infographic versions of the trial's website landing page (Experiment 1)
Number of subjects: 2979
Study 34653651 — intervention group
Group type: COMPARATOR
Intervention: Video versions of the trial's website landing page (Experiment 2)
Number of subjects: 2979
Study 33478718 — intervention group
Group type: EXPERIMENTAL
Intervention: Videos of newborn photographs with classical music (Group A)
Number of subjects: 273
Study 33478718 — intervention group
Group type: EXPERIMENTAL
Intervention: Video of the newborn photograph album (Group B)
Number of subjects: 273
Study 33478718 — intervention group
Group type: EXPERIMENTAL
Intervention: Introductory film of Turkey (Group C)
Number of subjects: 273
Study 33478718 — intervention group
Group type: EXPERIMENTAL
Intervention: Only classical music (Group D)
Number of subjects: 273
Study 33478718 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital care (Group E)
Number of subjects: 273
Study 35086112 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35% levobupivacaine (7 mL/h for 48 hours)
Number of subjects: 70
Study 35086112 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 70
Study 34601736 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen 800 mg
Number of subjects: 74
Study 34601736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 34601736 — intervention group
Group type: COMPARATOR
Intervention: IV ibuprofen 800 mg and Placebo
Number of subjects: 74
Study 32039811 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Talk About Smoking
Number of subjects: 162
Study 32039811 — intervention group
Group type: COMPARATOR
Intervention: NCI Education
Number of subjects: 162
Study 36100943 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality therapy (7 sessions within 12 weeks)
Number of subjects: 266
Study 36100943 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling (7 sessions within 12 weeks)
Number of subjects: 266
Study 36100943 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality therapy
Number of subjects: 266
Study 33636042 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE)
Number of subjects: 358
Study 34202578 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU oral vitamin D3
Number of subjects: 69
Study 34202578 — intervention group
Group type: COMPARATOR
Intervention: 1000 IU oral vitamin D3 (standard control)
Number of subjects: 69
Study 34202578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (5000 IU and 1000 IU)
Number of subjects: 69
Study 35239819 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reconciliation (MED)
Number of subjects: 100
Study 35239819 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CON)
Number of subjects: 100
Study 32272969 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ablation with an open‐irrigated ablation catheter equipped with CF sensing (used in a virtual nonirrigated modus)
Number of subjects: 0
Study 32272969 — intervention group
Group type: COMPARATOR
Intervention: Manual ablation with standard nonirrigated ablation catheters
Number of subjects: 0
Study 32272969 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ablation with open‐irrigated ablation catheter equipped with CF sensing
Number of subjects: 0
Study 35910820 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral ivermectin plus zinc sulfate for 3 days
Number of subjects: 113
Study 35910820 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine, darunavir/ritonavir, and zinc sulfate for 5 days
Number of subjects: 113
Study 34087468 — intervention group
Group type: EXPERIMENTAL
Intervention: RB-mediated PDT
Number of subjects: 45
Study 34087468 — intervention group
Group type: EXPERIMENTAL
Intervention: CUR-mediated PDT
Number of subjects: 45
Study 34087468 — intervention group
Group type: COMPARATOR
Intervention: Nystatin therapy
Number of subjects: 45
Study 33257257 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiology technologists measuring leg length discrepancies
Number of subjects: 4
Study 34078408 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned early delivery between 34+0 and 36+6 weeks
Number of subjects: 326
Study 34256988 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) plus specific exercises
Number of subjects: 42
Study 34256988 — intervention group
Group type: COMPARATOR
Intervention: Sham taping plus specific exercises
Number of subjects: 42
Study 35701062 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention (CM) including education and patient navigation for colorectal cancer screening.
Number of subjects: 153
Study 35701062 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counselling with an explanation of the screening process by psychiatric care providers.
Number of subjects: 153
Study 35701062 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention (CM) from the perspective of psychiatric care providers.
Number of subjects: 153
Study 36748363 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P17 (40 mg/0.4 ml)
Number of subjects: 205
Study 36748363 — intervention group
Group type: COMPARATOR
Intervention: EU-adalimumab (40 mg)
Number of subjects: 205
Study 36748363 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P17 and EU-adalimumab
Number of subjects: 205
Study 33587043 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine derivatives
Number of subjects: 396225
Study 33587043 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 396225
Study 35072795 — intervention group
Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 3012
Study 35072795 — intervention group
Group type: COMPARATOR
Intervention: Obese patients (BMI > 30)
Number of subjects: 3012
Study 35072795 — intervention group
Group type: COMPARATOR
Intervention: Overweight patients (BMI > 25)
Number of subjects: 3012
Study 35072795 — intervention group
Group type: COMPARATOR
Intervention: Overweight smokers
Number of subjects: 3012
Study 35072795 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 3012
Study 35072795 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 3012
Study 35072795 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival analysis
Number of subjects: 3012
Study 33855449 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (100 mg/kg IV q12h for 48h, then converted to oral therapy at the same dose)
Number of subjects: 61
Study 33855449 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 61
Study 33989086 — intervention group
Group type: EXPERIMENTAL
Intervention: Home medication review by community pharmacists (HMR-CP)
Number of subjects: 0
Study 33989086 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 35054148 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol
Number of subjects: 136
Study 35054148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 34277800 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified reverse sural neurofasciocutaneous flap with extended reconstruction range
Number of subjects: 24
Study 34277800 — intervention group
Group type: COMPARATOR
Intervention: Traditional reverse sural neurofasciocutaneous flap procedures
Number of subjects: 24
Study 36216274 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Partial Breast Irradiation (PBI) - 35 Gy in 10 daily fractions, with a 9 Gy boost in 3 fractions for patients with close margins
Number of subjects: 149
Study 36216274 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Partial Breast Irradiation (PBI)
Number of subjects: 149
Study 36216274 — intervention group
Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI) + boost
Number of subjects: 149
Study 32957859 — intervention group
Group type: EXPERIMENTAL
Intervention: GET FIT DON'T QUIT intervention
Number of subjects: 37
Study 32957859 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 32700191 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous infusions of felbinac trometamol (11.78–377.00 mg)
Number of subjects: 92
Study 32700191 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple intravenous infusions of felbinac trometamol (47.13–188.50 mg)
Number of subjects: 92
Study 32700191 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbinac trometamol (various doses)
Number of subjects: 92
Study 35762432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model for predicting the risk of death during hospitalization
Number of subjects: 1714
Study 33611240 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham 2008 risk score
Number of subjects: 606
Study 33611240 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORE (low and high-risk populations)
Number of subjects: 606
Study 33611240 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP III risk score
Number of subjects: 606
Study 33611240 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization-American B region (WHO-B)
Number of subjects: 606
Study 33611240 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Cohort equations (PC)
Number of subjects: 606
Study 33611240 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fatal cardiovascular events (CVE)
Number of subjects: 606
Study 33611240 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cardiovascular deaths
Number of subjects: 606
Study 33611240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular deaths
Number of subjects: 606
Study 34081484 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay Smoking Task (n = 39)
Number of subjects: 75
Study 34081484 — intervention group
Group type: COMPARATOR
Intervention: Posture Task (n = 36)
Number of subjects: 75
Study 34081484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both task groups
Number of subjects: 75
Study 34081484 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay Smoking Task
Number of subjects: 75
Study 34654364 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based instruction
Number of subjects: 72
Study 34654364 — intervention group
Group type: COMPARATOR
Intervention: Conventional lecture
Number of subjects: 72
Study 34654364 — intervention group
Group type: COMPARATOR
Intervention: Nurses
Number of subjects: 72
Study 34654364 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal ward clinicians
Number of subjects: 72
Study 35500171 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin with PPIs
Number of subjects: 15839
Study 35500171 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 15839